FGFR3 and urinary bladder carcinoma: Promising results were recently reported for four out of the five patients with FGFR3‐mutated bladder cancers enrolled in a phase I clinical trial of the pan‐FGFR kinase inhibitor BGJ398 (Nogova et al, 2017).